Government Awards for Biothreat Initiatives
 

BARDA Contract for Eravacycline:

In February 2012, Tetraphase announced that the Biomedical Advanced Research and Development Authority (BARDA) had awarded a contract worth up to $67 million for the development of eravacycline, a potent new antibiotic effective against multidrug-resistant Gram-negative pathogens and the lead product candidate in Tetraphase's clinical pipeline. Tetraphase is collaborating on this contract with Buffalo, NY-based CUBRC, Inc.

CUBRC serves as the prime contractor under the BARDA contract, primarily carrying out a program management and administrative role with additional responsibility for the management of certain preclinical studies. Tetraphase serves as lead technical expert on all aspects of the BARDA contract and serves as a subcontractor responsible for management of chemistry, manufacturing and control activities and clinical studies.

In connection with the BARDA contract, in February 2012, Tetraphase entered into with CUBRC a five-year cost plus-fixed-fee subcontract under which Tetraphase may receive funding of up to approximately $40 million, reflecting the portion of the BARDA funding that may be paid to Tetraphase for its activities.

NIAID Awards for TP-271:

During the second half of 2011, the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a contract worth up to $36 million and a grant valued up to $4.3 million for the development of TP-271, Tetraphase’s novel antibiotic for respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens. Tetraphase is collaborating on these awards as a sub-contractor to Buffalo, NY-based CUBRC, Inc.

The NIAID awards cover development, manufacturing, and clinical activities to position TP-271 for further development against certain biothreat agents, including Francisella tularensis, which causes tularemia, Yersinia pestis, which causes bubonic plague, and Bacillus anthracis, which causes anthrax disease, and bacterial pathogens associated with community-acquired bacterial pneumonia (CABP), a significant public health threat and commercial market opportunity.

CUBRC serves as the prime contractor under the NIAID awards, primarily carrying out a program management and administrative role, though also with responsibility for the management of certain preclinical studies under the NIAID contract. Tetraphase serves as the lead technical expert on all aspects of the NIAID awards and serves as the subcontractor responsible for management of chemistry, manufacturing and control activities and clinical studies.

In connection with the NIAID contract, in October 2011, Tetraphase entered into with CUBRC a five-year cost-plus-fixed-fee subcontract under which Tetraphase may receive funding of up to approximately $13 million, reflecting the portion of the NIAID contract funding that may be paid to Tetraphase for its activities. In connection with the NIAID grant, in November 2011, CUBRC awarded Tetraphase a 55-month, no-fee subaward of approximately $1 million, reflecting the portion of the NIAID grant funding that may be paid to Tetraphase for its activities.

 

Print this Page  
Entire Movie Background Platform Chemical Diversity